Learn More
KAL1 Polyclonal Antibody, Invitrogen™
Rabbit Polyclonal Antibody
Marque: Invitrogen PA5101428
322.01 EUR valable jusqu'au 2025-03-21
Utilisez le code promo "24111" pour bénéficier de cette offre.
Alert:
Pour que la promotion s’applique, le client doit acheter trois fois le même produit au prix catalogue sur la même commande pour avoir une remise de 33.33%. Il n’y a pas de limite d’achat pour un multiple de 3 produits. PCODE: 24111
Description
Antibody detects endogenous levels of total KAL1.
KAL1 (Anosmin-1) an extracellular matrix-associated glycosylated protein, have been linked with Kallmann Syndrome (KS), an X-linked genetic disorder characterized by loss of smell caused by abnormal olfactory bulb development and delayed puberty caused by disrupted migration of the gonadotropin-releasing hormone neuron. Anosmin-1 has been shown to directly bind FGFR1 via its N-terminal cysteine-rich domain, whey-acidic protein-like domain, and its first FnIII repeat with the D2 and D3 ectodomains of FGFR1. It is thought that Anosmin-1 can modulate FGFR1 signaling and have opposing effects on the formation and activation of FGF2-FGFR1-heparing complex.
Spécification
KAL1 | |
Polyclonal | |
Unconjugated | |
ANOS1 | |
Adhesion molecule-like X-linked; ADMLX; ANOS1; anosmin; anosmin 1; Anosmin1; anosmin-1; HH1; HHA; KAL; KAL1; KALIG1; KALIG-1; Kallmann syndrome interval gene 1; kallmann syndrome protein; Kallmann syndrome-1 sequence (anosmin-1); KMS; WAP four-disulfide core domain 19; WFDC19 | |
Rabbit | |
Affinity chromatography | |
RUO | |
3730 | |
-20°C | |
Liquid |
Immunocytochemistry, Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P23352 | |
ANOS1 | |
A synthesized peptide derived from human ANOS1(Accession P23352), corresponding to amino acid residues K162-I212. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Suggestions de produits
Clients qui ont consulté cet article ont également consulté
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.